Neuren Pharmaceuticals (ASX:NEU) has received Fast Track designation from the US Food and Drug Administration for its investigational therapy NNZ-2591 for the treatment of Phelan-McDermid syndrome, a rare neurodevelopmental disorder with no approved therapies. …
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 Australian BiotechLatest Video
New Stories
-
Medicines Australia seeks answers on AI in HTA process
September 23, 2026 - - Latest News -
The prevention gap and inside Sally Panton's bet on cellular health
September 23, 2026 - - Latest News -
Pfizer 'deeply disappointed' in response to PBAC refusing to move on price
September 23, 2026 - - Latest News -
Lilly goes direct with a patient platform for its non-PBS medicines
September 23, 2026 - - Latest News -
A 'multistakeholder' reference group to shadow agreement negotiations
September 23, 2026 - -
If there is a productivity gain in the process, then it should be passed on
September 22, 2026 - - Latest News -
Given the official use of AI, a cease and desist would not be unreasonable
September 22, 2026 - - Latest News